Evidence map›Paper›PMID 35420360›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2022

Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing-remitting multiple sclerosis in Italy.

Carlo Lazzaro, Roberto Bergamaschi, Mauro Zaffaroni, Rocco Totaro, Damiano Paolicelli

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Carlo LazzaroStudio di Economia Sanitaria, Via Stefanardo da Vimercate, 19, 20128, Milan, Italy. carlo.lazzaro@tin.it.ORCID http://orcid.org/0000-0003-4795-1834
Roberto BergamaschiIRCCS Mondino Foundation, Pavia, Italy.ORCID http://orcid.org/0000-0002-1397-511X
Mauro ZaffaroniMultiple Sclerosis Centre, Hospital of Gallarate, ASST Della Valle Olona, Gallarate, Italy.ORCID http://orcid.org/0000-0001-9020-934X
Rocco TotaroCentro Malattie Demielinizzanti, Ospedale San Salvatore, L'Aquila, Italy.ORCID http://orcid.org/0000-0001-5852-7743
Damiano PaolicelliDepartment of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro", Bari, Italy.ORCID http://orcid.org/0000-0002-8645-1763
Azienda Ospedaliera di Desio e Vimercate · ITAzienda Ospedaliera Sant’Antonio Abate di Gallarate · ITSan Salvatore Hospital · ITUniversity of Bari Aldo Moro · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultiple sclerosis (MS) accounts for 176 cases per 100,000 inhabitants (female/male ratio = 2:1) in Italy. For most of the patients (67%), the disease course is relapsing-remitting MS (RRMS).

objectiveTo compare the costs and quality-adjusted life years (QALYs) of teriflunomide in RRMS naïve patients vs. RRMS patients previously treated (experienced) with other disease-modifying therapies in Italy.

methodsA four health states Markov model-supported cost-utility analysis (CUA) covering a 7-year timespan through annual cycles was developed, following the healthcare sector and the societal viewpoints. Part of the parameters that populated the Markov model was obtained from a questionnaire administered to four primary Italian MS centres. Costs of healthcare and non-healthcare resources, expressed in euro (€) 2019, and QALYs were discounted at 3% real social discount rate. One-way, scenario and probabilistic sensitivity analyses tested the uncertainty of the baseline findings.

resultsBaseline CUA shows that teriflunomide in RRMS naïve patients is strongly dominant vs. experienced patients (healthcare sector perspective: - €1042.68 and + 0.480 QALYs; societal perspective: - €6782.81 and + 0.480 QALYs). Sensitivity analyses confirmed the robustness of the baseline results.

conclusionTeriflunomide in RRMS naïve vs. experienced patients is cost-effective and possibly strongly dominant from both the healthcare sector and the society viewpoints in Italy. Our findings need further confirmation from real-world studies.

Indexed as

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingCost-Benefit AnalysisCrotonatesFemaleHumansHydroxybutyratesImmunosuppressive AgentsMaleMarkov ChainsNitrilesToluidinesCrotonatesHydroxybutyratesImmunosuppressive AgentsNitrilesteriflunomideToluidinesCost-utility analysisDisease-modifying treatmentItalyMarkov modelRelapsing–remitting multiple sclerosisTeriflunomide

Identifiers

PMID35420360
PMCPMC9349140
OpenAlexW4223998482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.